YANG Jin-ji, KANG Jin. The First International, Multicentre, Open-Label, Single-Arm Trial about Lorlatinib in Non-Small Cell Lung Cancer with ALK or ROS1 Rearrangement[J]. Journal of Evidence-Based Medicine, 2018, 18(1): 43-47. DOI: 10.12019/j.issn.1671-5144.2018.01.014
|
Citation:
|
YANG Jin-ji, KANG Jin. The First International, Multicentre, Open-Label, Single-Arm Trial about Lorlatinib in Non-Small Cell Lung Cancer with ALK or ROS1 Rearrangement[J]. Journal of Evidence-Based Medicine, 2018, 18(1): 43-47. DOI: 10.12019/j.issn.1671-5144.2018.01.014
|
YANG Jin-ji, KANG Jin. The First International, Multicentre, Open-Label, Single-Arm Trial about Lorlatinib in Non-Small Cell Lung Cancer with ALK or ROS1 Rearrangement[J]. Journal of Evidence-Based Medicine, 2018, 18(1): 43-47. DOI: 10.12019/j.issn.1671-5144.2018.01.014
|
Citation:
|
YANG Jin-ji, KANG Jin. The First International, Multicentre, Open-Label, Single-Arm Trial about Lorlatinib in Non-Small Cell Lung Cancer with ALK or ROS1 Rearrangement[J]. Journal of Evidence-Based Medicine, 2018, 18(1): 43-47. DOI: 10.12019/j.issn.1671-5144.2018.01.014
|
DownLoad: